SLNO
Soleno Therapeutics, Inc. [SLNO] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
SLNO Stock Summary
Top 10 Correlated ETFs
SLNO
Top 10 Correlated Stocks
SLNO
In the News
SLNO Financial details
Company Rating
-
Market Cap
1.21B
Income
-38.98M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-15.2
Forward P/E
-
PEG
-6.69
P/S
-
P/B
20.57
P/C
-
P/FCF
-53.58
Quick Ratio
1.81
Current Ratio
1.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.97
EPS next Y
-
EPS next Q
-
EPS this Y
-2.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-65.26%
-
-
-
-
SMA20
38.78%
SMA50
36%
SMA100
25.93%
Inst Own
-
Inst Trans
-
ROA
-49%
ROE
-259%
ROC
-0.97%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.82-53.82
52W High
+31.04%
52W Low
+3372.5%
RSI
63
Rel Volume
1.52
Avg Volume
300.3K
Volume
455.43K
Perf Week
10.47%
Perf Month
59%
Perf Quarter
26.46%
Perf Half Y
28.23%
-
-
-
-
Beta
-1.543
-
-
Volatility
0.97%, 10.13%
Prev Close
-0.76%
Price
69.45
Change
13.02%
Company Profile
- Volume Average 300.3K
- Market Capitalization 1.21B
- Employee 33
- CEO Dr. Anish Bhatnagar M.D.
- Headquarters Redwood City,CA,US
- IPO Date 2014-11-13
-
Website
https://soleno.life 
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
